Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity - PubMed (original) (raw)

Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity

D Schadendorf et al. Cancer. 1994.

Abstract

Background: Clinical response rates in the treatment of patients with disseminated malignant melanoma are low and unpredictable. Several reports have documented that clonogenic assay systems for in vitro drug testing are capable of predicting resistance to therapy in vivo and might provide guidelines to improve clinical response rates.

Methods: Specimens from metastatic lesions of patients with malignant melanoma, predominantly from lymph nodes and skin, were disaggregated, exposed to a panel of 10 cytotoxic drugs for 1 hour, and subsequently cultured in agarose. Effects were calculated by the ability to form tumor colonies compared with an untreated control after 7-14 days. A retrospective comparison between the in vitro drug testing result and clinical response was possible in 19 cases.

Results: An average of 7.3 drugs per specimen were tested. A high degree of resistance was observed against all cytostatic agents studied independently of the tumor site. In 47 of 181 in vitro drug tests, tumor colony formation was reduced by 30-50%; in 17 of 181, the reduction was more than 50%. A retrospective analysis showed no clinical response in 11 cases and one mixed response in which patients received drugs that had been shown to be "resistant" in vitro.

Conclusions: These results support the concept that in vitro drug testing promises to help avoid treatment with ineffective drugs and their associated toxic side effects. Furthermore, it may increase the likelihood of obtaining a clinical response in the treatment of disseminated malignant melanoma. The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment.

PubMed Disclaimer

Cited by

The Melding of Drug Screening Platforms for Melanoma.
Couto GK, Segatto NV, Oliveira TL, Seixas FK, Schachtschneider KM, Collares T. Couto GK, et al. Front Oncol. 2019 Jun 24;9:512. doi: 10.3389/fonc.2019.00512. eCollection 2019. Front Oncol. 2019. PMID: 31293965 Free PMC article. Review.
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D. Möller P, et al. Br J Cancer. 1998 Jun;77(11):1907-16. doi: 10.1038/bjc.1998.317. Br J Cancer. 1998. PMID: 9667667 Free PMC article. Clinical Trial.
Membrane transport proteins associated with drug resistance expressed in human melanoma.
Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM. Schadendorf D, et al. Am J Pathol. 1995 Dec;147(6):1545-52. Am J Pathol. 1995. PMID: 7495278 Free PMC article.
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.
Riedl S, Zweytick D, Lohner K. Riedl S, et al. Chem Phys Lipids. 2011 Nov;164(8):766-81. doi: 10.1016/j.chemphyslip.2011.09.004. Epub 2011 Sep 16. Chem Phys Lipids. 2011. PMID: 21945565 Free PMC article. Review.
Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.
Böhm M, Möller P, Kalbfleisch U, Worm M, Czarnetzki BM, Schadendorf D. Böhm M, et al. Br J Cancer. 1994 Jul;70(1):54-9. doi: 10.1038/bjc.1994.249. Br J Cancer. 1994. PMID: 8018541 Free PMC article.

Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity - PubMed (original) (raw)